Sustainable Synthesis of Guanidine Derivatives and Computational Assessment of their Antidiabetic Efficacy.

Endocrine, metabolic & immune disorders drug targets Pub Date : 2024-07-02 DOI:10.2174/0118715303287962240621053459

Imkongyanger, Kikoleho Richa, Tsenbeni N Lotha, Ketiyala Ao, Lemzila Rudithongru, Vevosa Nakro, Vimha Ritse, Nima D Namsa, Pranay Punj Pankaj, Upasana Bora Sinha, Latonglila Jamir

{"title":"Sustainable Synthesis of Guanidine Derivatives and Computational Assessment of their Antidiabetic Efficacy.","authors":"Imkongyanger, Kikoleho Richa, Tsenbeni N Lotha, Ketiyala Ao, Lemzila Rudithongru, Vevosa Nakro, Vimha Ritse, Nima D Namsa, Pranay Punj Pankaj, Upasana Bora Sinha, Latonglila Jamir","doi":"10.2174/0118715303287962240621053459","DOIUrl":null,"url":null,"abstract":"Background: Type 2 Diabetes Mellitus (T2DM) represents a significant and pressing worldwide health concern, necessitating the quest for enhanced antidiabetic pharmaceuticals. Guanidine derivatives, notably metformin and buformin, have emerged as pivotal therapeutic agents for T2DM management.Aims: The present study introduces an efficient one-pot synthesis method for the production of symmetrical guanidine compounds.Methods: This synthesis involves the reaction of isothiocyanates with secondary amines, employing an environmentally friendly and recyclable reagent, tetrabutylphosphonium tribromide (TBPTB).Results: A comprehensive assessment of the biological activity of the synthesized guanidine compounds, specifically in the context of T2DM, has been rigorously conducted.Conclusion: Additionally, computational analyses have unveiled their substantial potential as promising antidiabetic agents. Results highlight the relevance of these compounds in the ongoing pursuit of novel therapeutic solutions for T2DM..","PeriodicalId":94316,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715303287962240621053459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 Diabetes Mellitus (T2DM) represents a significant and pressing worldwide health concern, necessitating the quest for enhanced antidiabetic pharmaceuticals. Guanidine derivatives, notably metformin and buformin, have emerged as pivotal therapeutic agents for T2DM management.

Aims: The present study introduces an efficient one-pot synthesis method for the production of symmetrical guanidine compounds.

Methods: This synthesis involves the reaction of isothiocyanates with secondary amines, employing an environmentally friendly and recyclable reagent, tetrabutylphosphonium tribromide (TBPTB).

Results: A comprehensive assessment of the biological activity of the synthesized guanidine compounds, specifically in the context of T2DM, has been rigorously conducted.

Conclusion: Additionally, computational analyses have unveiled their substantial potential as promising antidiabetic agents. Results highlight the relevance of these compounds in the ongoing pursuit of novel therapeutic solutions for T2DM.

查看原文本刊更多论文

胍类衍生物的可持续合成及其抗糖尿病功效的计算评估。

背景：2 型糖尿病（T2DM）是一个重大而紧迫的全球健康问题，因此有必要寻求更好的抗糖尿病药物。胍类衍生物，尤其是二甲双胍和布福明，已成为治疗 T2DM 的关键药物。目的：本研究介绍了一种生产对称胍类化合物的高效单锅合成方法：该合成涉及异硫氰酸酯与仲胺的反应，使用了一种环境友好且可回收的试剂--四丁基三溴化磷（TBPTB）：结果：对合成的胍类化合物的生物活性进行了严格的综合评估，特别是在治疗 T2DM 方面：此外，计算分析揭示了这些化合物作为有前途的抗糖尿病药物的巨大潜力。结论：此外，计算分析还揭示了这些化合物作为有前途的抗糖尿病药物的巨大潜力。研究结果凸显了这些化合物在不断寻求 T2DM 新型治疗方案方面的相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine, metabolic & immune disorders drug targets

自引率

0.00%

发文量